MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis
Damiano Rondelli(University of Illinois Chicago), Robert S. Hoffman(New York City Department of Health and Mental Hygiene), Rebecca B. Klisovic(Goethe University Frankfurt), Luis Isola(Mount Sinai Medical Center), Attilio Orazi(Texas Tech University), Meir Wetzler, Josef T. Prchal(Huntsman Cancer Institute), Vesna Najfeld, Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Rona Singer Weinberg(University of North Carolina at Chapel Hill), Björn Andréasson(NU Hospital Group), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Vikas Gupta(Indian Institute of Technology Kanpur), Marco Scarano(Mario Negri Sud Foundation), Tsiporah B. Shore(Cornell University), John Mascarenhas(Tisch Hospital), Leah Price(Cwm Taf University Health Board), Michael Boyer(Chris O’Brien Lifehouse), Giovanni Barosi(Policlinico San Matteo Fondazione), Andrea Bacigalupo(Università Cattolica del Sacro Cuore), Crystal Miller(Mount Sinai Medical Center), Lewis R. Silverman(Icahn School of Medicine at Mount Sinai), Judith D. Goldberg(New York University), Roberto Marchioli, Giuseppe Prosperini(Mario Negri Sud Foundation)
Cited by 153
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k